Shots:

• Sarepta to receive $1.15B up front including $750M in cash $400M in Sarepta stock- priced at $158.59/share of common stock- up to $1.7B regulatory and sales milestones plus royalties on sales. Sarepta will be responsible for SRP-9001’s clinical development and manufacturing with global clinical cost equally shared
• Roche to get exclusive rights to commercialize Sarepta’s SRP-9001 outside the US for Duchenne muscular dystrophy (DMD). Additionally- Roche has an option to acquire ex-US rights for certain DMD products from Sarepta in exchange of milestone and royalty considerations- and cost sharing
• SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) is an investigational gene therapy candidate targeted for DMD designed to deliver micro-dystrophin-encoding gene directly to the muscle tissue for the targeted production of the micro-dystrophin protein. The transaction is expected to close in Q1’20 

Click here to read full press release/ article

Ref: Sarepta| Image: Roche